scispace - formally typeset
C

Charbel Moussa

Researcher at Georgetown University Medical Center

Publications -  129
Citations -  14468

Charbel Moussa is an academic researcher from Georgetown University Medical Center. The author has contributed to research in topics: Parkin & Neurodegeneration. The author has an hindex of 36, co-authored 118 publications receiving 12111 citations. Previous affiliations of Charbel Moussa include Mines ParisTech & Intelligence and National Security Alliance.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky, +1287 more
- 01 Apr 2012 - 
TL;DR: These guidelines are presented for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer's disease.

Charbel Moussa, +6 more
- 03 Jan 2017 - 
TL;DR: Data suggest that resveratrol decreases CSF MMP9, modulates neuro-inflammation, and induces adaptive immunity, and SIRT1 activation may be a viable target for treatment or prevention of neurodegenerative disorders.
Journal ArticleDOI

Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of α-synuclein in Parkinson's disease models

Michaeline Hebron, +2 more
- 15 Aug 2013 - 
TL;DR: Nilotinib is used for adult leukemia treatment and it enters the brain within US Food and Drug Administration approved doses, leading to autophagic degradation of α-synuclein, protection of SN neurons and amelioration of motor performance, suggesting that nilotinib may be a therapeutic strategy to degrade α- Synuclein in PD and other α- synucleinopathies.
Journal ArticleDOI

Amyloid precursor protein secretases as therapeutic targets for traumatic brain injury

David J. Loane, +7 more
- 15 Mar 2009 - 
TL;DR: It is shown that blocking either β- or γ-secretase, enzymes required for production of Aβ from amyloid precursor protein (APP), can ameliorate motor and cognitive deficits and reduce cell loss after experimental TBI in mice.